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Visual inspection may fail to accurately evaluate field 
cancerisation (subclinical actinic keratoses [AKs]). We 
aimed to describe field cancerisation by confocal reflec-
tance microscopy and changes induced by the application 
of 3% diclofenac sodium gel in 2.5% hyaluronic acid. 
Fourteen male patients > 50 years old with AKs on the 
bald scalp were included. Clinical examination, confo-
cal microscopy and histological study of clinically visible 
lesions and “normal appearing” adjacent skin before 
and after treatment was completed. Reflectance confocal 
microscopy showed a decrease in scaling (p = 0.001) and 
atypia of the honeycomb pattern (p = 0.001) at 2 weeks of 
treatment. Changes in parakeratosis, inflammation and 
dermal collagen remodelling were also observed. Histo-
logy correlated with confocal features in AK and sub-
clinical AK. Reflectance confocal microscopy was useful 
in the evaluation of field cancerisation and monitoring 
of treatment response. A rapid improvement in epider-
mal atypia was observed. Key words: field cancerisation; 
actinic keratosis; reflectance confocal microscopy; histo-
logy; diclofenac; hyaluronic acid. 
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In the skin, “field cancerisation” (1, 2) describes sub-
clinical lesions with “normal appearing skin” surroun-
ding clinically visible actinic keratosis (AK), providing 
the basis for clonal expansion of genetically altered 
neoplastic cells (1–5). The diagnosis of AK is generally 
based on clinical examination. However, biopsy and his-
tological evaluation are performed in clinically indistinct 
cases, or if invasive squamous cell carcinoma (SCC) is 
suspected. While visual inspection may fail to detect 
early subclinical changes, repeated invasive histological 
analysis of areas with extensive actinic damage often 
may not be feasible. 
AKs are commonly present in areas of chronic actinic 
damage. Histologically, AKs have been classified ac-
cording to keratinocyte atypia, nuclear pleomorphism, 
hyperkeratosis, parakeratosis, a dermal inflammatory 
infiltrate and concomitant solar elastosis (6). AK is one 
stage of a biologic continuum in the progression from 
subclinical keratinocyte dysplasia to invasive SCC 
(7–12). However, in the clinical setting, patients often 
present with numerous AKs at various stages of graded 
differentiation and the extent of subclinical disease is 
difficult to determine. 
In thinking about the various diagnostic modalities 
currently available, it is clear that a diagnosis based on 
clinical grounds alone may not be sufficiently reliable, 
while the feasibility of obtaining biopsies of all affected 
sides and surrounding skin is limited. Hence, in recent 
years interest has risen in the development of novel 
non-invasive diagnostic techniques that not only allow 
precise diagnosis of clinical AKs but also allow detection 
and definition of subclinical disease. In vivo reflectance 
confocal microscopy (RCM) generates horizontal skin 
sections with quasi-histological resolution. Its use in the 
detection of AKs and field cancerisation, as well as the 
evaluation of response to topical treatments has been 
clearly established (5, 13–16). 
Several new therapeutic options have become avail-
able over recent years, and there remains debate about 
the best treatment options for AKs and field cancerisa-
tion. Treatment options for AKs include a wide range 
of ablative modalities and topical treatments such as 
diclofenac sodium gel, imiquimod, ingenol mebutate 
gel or 5-fluorouracil with salicylic acid. Diclofenac 
sodium 3% gel is a non-steroidal anti-inflammatory 
topical agent that demonstrates preferential inhibition of 
cyclo-oxygenase-2 (COX-2), an enzyme implicated in 
ultraviolet (UV)-induced skin carcinogenesis (17–27). 
The treatment of AKs with topical 3% diclofenac in 
2.5% hyaluronic acid (Solaraze®, Almirall, S.A., Barce-
lona, Spain) has been extensively documented in the last 
decade (17). However, precise information regarding 
in vivo morphological changes induced by this drug in 
the skin is needed. In the present study we aimed to 
describe the changes in the skin of patients with clinical 
and subclinical AK during and after topical treatment 
with 3% diclofenac sodium with 2.5% hyaluronic acid 
by RCM, and describe the correlation between RCM 
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and histology. The study was not designed to assess 
clinical response or to compare this drug with other 
alternatives but to demonstrate the changes in vivo 
induced by the drug.
MATeRIAl AnD MeTHODS
Twenty volunteer male patients, aged >50 years old, 
Fitzpatrick’s skin phototype I–III, with a minimum of 3 clini-
cally visible AK on the bald scalp, were included in this study. 
Written informed consent was obtained from each participant 
before evaluation. Evaluation consisted of clinical examina-
tion, dermoscopic imaging and RCM evaluation of a clinically 
visible AK and “normal appearing” adjacent skin. In each par-
ticipant, lesions clinically diagnosed as AK were selected for 
imaging and biopsy as well as adjacent, apparently unaffected 
skin. An area of 2 × 2 cm on the scalp including at least 3 AK 
was selected. At the first visit, a 3-mm punch biopsy was perfor-
med in one AK and another 3-mm punch biopsy was performed 
in normally apparent surrounding skin (subclinical AK) (Fig. 
1). Additionally, one clinical AK and one subclinical AK were 
also selected at baseline (t1) to be biopsied at the end of the 
treatment (t4). Transparency body charts were used to outline 
the selected skin areas at baseline and to permit co-localisation. 
Highlighted skin areas were documented on the chart by using 
permanent marker pens in a colour-coded fashion, correlating 
individual colours to selected evaluation dates. Evaluation 
with reflectance confocal microscopy was performed before 
treatment (time 1), at week 2 (time 2), at week 6 (time 3), at 
end of treatment (time 4) in 4 sub-areas (8 × 8 mm) inside the 
selected 2 × 2 cm area. Sites of biopsies at t1 were avoided for 
the RCM evaluation.
Following the approved indication treatment with topical 
diclofenac sodium 3% in 2.5% hyaluronic acid was applied 
twice daily for 90 days over the affected skin area, covering both 
clinically affected AKs and apparently unaffected adjacent skin. 
A commercially available in vivo reflectance confocal micros-
cope (Vivascope 1500, lucid-Tech, Inc., Henrietta, nY, USA; 
MAVIg gmbH, Munich, germany) was used to image AKs and 
surrounding “normal appearing” skin. A detailed description 
of the technique and the device has been published previously 
(13–15). For each skin site analysed, systematic horizontal 
mapping was performed and 4–8 images were captured in 
axial sections beginning with the stratum corneum, through the 
entire epidermis and into the upper reticular dermis using the 
“Vivablock” function modality (each vivablock was 16 × 16 = 
254 images composite). Furthermore, a vertical mapping using 
the “Vivastack” was performed in 5 µm steps to a maximum 
depth of 200 µm beginning with the stratum corneum through 
the entire epidermis and into the superficial dermis. RCM 
images were individually subjected to evaluation. 
Diagnostic RCM criteria for AK are shown in Table SIa1. 
Diagnostic criteria for AK included parakeratosis, hyperkera-
tosis, individual detached keratinocytes, architectural disarray, 
keratinocyte atypia and pleomorphism as shown in Table SI1. 
An investigator obtained images of all test sites (RR). The 
corresponding RCM images were then subject to blinded eva-
luation by 2 independent experts in the field of confocal mi-
croscopy (JM and SP). evaluators were blinded to participant’s 
name, age and treatment duration.
Skin punch biopsies (4 mm in diameter) were obtained under 
sterile conditions after local anaesthesia with lidocaine 1% from 
a previously selected skin lesion clinically diagnosed as AK, 
and also from apparently unaffected adjacent skin at t1 and end 
of treatment (t4). The skin samples were fixed in 10% formalin 
and processed by routine histopathology. Staining with haema-
toxylin and eosin was performed and slides were evaluated by a 
board-certified pathologist (AD). Immunohistochemical stains 
were performed to evaluate COX-2 expression, p53 mutation, 
Ki67, PCnA, p21 and CD31 before and at the end of treatment. 
The histopathological and immunohistochemical scores used 
are detailed in Table SIb1. 
Statistical analysis
The statistical analyses for categorical variables were perfor-
med with a chi-squared test, or Fisher’s test for 2 × 2 tables 
when required depending on the sample size. For continuous 
variables; the mean score for each parameter before treatment 
(t1; histology or RCM) was compared with the mean score 
during (t2, t3, RCM) and at the end of the study (t4; histology 
and RCM) using Student t-test for paired samples for normally 
distributed data. AnOVA was used for multiple comparisons 
at different times (t1, t2, t3, t4). 
ReSUlTS
At the end of the study 14 patients were able to complete 
the treatment course and evaluation. Six patients dropped 
out of the study. Two patients withdrew consent and did 
not follow-up with treatment or evaluation after inclusion 
(t1). Four patients were excluded from the study during 
the treatment course because they were unwilling to 
continue with treatment or follow-up due to local adverse 
Fig. 1.  Actinic keratosis (a) and subclinical actinic 
keratosis (b) by routine histology (H&e) (× 100). 
Presence of parakeratosis, architectural disarray, 
keratinocyte atypia seen to a varying degree.
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-1860
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skin reaction to the topical application of 3% diclofenac 
sodium with 2.5% hyaluronic acid. These local adverse 
events consisted mainly of moderate to severe erythema, 
mild to moderate scaling, dryness and pruritus. 
A total of 59,136 RCM images were obtained. The 
presence of scaling, the area of atypical honeycomb 
and the degree of atypical honeycomb decreased after 
2 weeks of treatment (p = 0.001; p = 0.002; p = 0.000). 
These changes persisted after the end of treatment 
(p = 0.000 for all 3) (Fig. 2). After 2 weeks of treatment, 
the presence of polygonal nucleated cells, detached 
individual corneocytes and inflammation increased 
(p = 0.003, p = 0.004; p = 0.002) (Table SII1) (Figs 3 and 
4). These increases in polygonal nucleated upper cells 
and detached corneocytes were normalised at the end 
of treatment (p = 0.696; p = 0.311) (Table SII1). On the 
contrary, an elevated level of inflammation persisted 
during the entire period of study (p = 0.025) showing the 
presence of small bright inflammatory cells and some 
dendritic cells in the spinous cell layer as well as in 
the upper dermis (Fig. 4). Changes in dermal collagen 
thickening and arrangement of fibres in the upper dermis 
were observed at the end of treatment (Fig. 5). Huddles 
of collagen and curled fibres, that have been described 
in elastosis, were replaced by aligned thinner fibres.
Histology before and after the treatment course sho-
wed an important reduction in epidermal atypia in AK 
(p = 0.001) and subclinical AK (p = 0.003) between t1 and 
t4. Immunohistochemical analysis demonstrated a reduc-
tion in cellular proliferation measured by the expression 
of Ki67 in AK (p = 0.02) and subclinical AK (p = 0.023) 
at the end of treatment. In subclinical AKs, there was a 
marked reduction in the expression of the vascular marker 
CD31 (p = 0.017) after treatment. evaluation of COX-2 
Fig. 2. Reflectance confocal microscopy (RCM) 
image (vivablock 1.2 mm2) with atypical honeycomb 
in the stratum spinosum of a subclinical actinic 
keratosis at time 0 before treatment (a). Presence of 
atypical keratinocytes with irregular size, shape and 
refractivity (white arrows). On the right image (b) 
RCM of the same lesion after the treatment at time 
4. normalisation of honeycomb pattern in the same 
lesion is clearly seen.
Fig. 3. Reflectance confocal microscopy image at the stratum corneum 
(0.5 × 0.5 µm) at week 2. Dyskeratosis with presence of nucleated cells 
(black arrows) and discohesive keratinocytes (white arrows).
Fig. 4. Presence of inflammatory cells (white arrows) at 
time 2 of treatment in subclinical actinic keratosis seen 
under reflectance confocal microscopy in the stratum 
spinosum of the epidermis (0.5 × 0.5 mm) with round 
nucleated cells corresponding to lymphocytes (a) and 
dendritic cells corresponding to langerhans’ cells (b).
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expression was available in just 7 paired AK and 7 paired 
subclinical AK samples (t1–t4) decreasing significantly 
in AK (p = 0.047) but just showing a tendency to decrease 
in subclinical AK (p = 0.078) (Table I).
DISCUSSIOn
AK is the most common in situ carcinoma of the skin, 
the incidence of which is increasing in many world 
populations (19, 28, 29). The relative risk of SCC in-
creases with the number of AK lesions with an increase 
from 1% in those with fewer than 5 lesions to 20% in 
those with more than 20 lesions (30–32). Subclinical 
(invisible) AKs are estimated to occur up to 10 times 
more frequently than visible AKs, particularly in 
sun-damaged skin (33). Currently it is not possible 
to determine which AK lesion will progress to SCC 
by clinical or histopathological means (34, 35). Thus, 
early adequate diagnosis and treatment of all visible 
and subclinical lesions is recommended to reduce the 
Fig. 5. Reflectance confocal microscopy image of the 
upper dermis showing changes in the collagen in a 
subclinical actinic keratosis before treatment at time 
0 (a) and after treatment at time 4 (b). Huddles of 
collagen and curled fibres, corresponding to elastosis 
are replaced by aligned thinner fibres.
Table I. Comparison of immunohistopathological findings in actinic keratosis and subclinical actinic keratosis lesions at baseline and 
at the end of treatment 
Actinic keratosis Subclinical actinic keratosis
Mean n
Deviation 
typical
Error typical 
of the mean p-value Mean n
Deviation 
typical
Error typical 
of the mean p-value
Epidermal thickness t1 0.90 10 0.876 0.277 0.25 0.40 10 0.516 0.163 0.081
t4 0.20 10 0.422 0.133 0.10 10 0.316 0.100
Thickness of stratum corneum t1 1.60 10 0.516 0.163 0.19 0.80 10 0.632 0.200 0.394
t4 0.70 10 0.675 0.213 1.10 10 0.738 0.233
Epidermal atypia t1 2.00 10 0.000 0.000 0.001 1.70 10 0.483 0.153 0.003
t4 1.30 10 0.483 0.153 0.90 10 0.568 0.180
Thickness of atypia t1 1.40 10 0.516 0.163 0.037 1.00 10 0.000 0.000 0.168
t4 1.00 10 0.000 0.000 0.80 10 0.422 0.133
Inflammation t1 1.20 10 0.632 0.200 0.168 0.40 10 0.516 0.163 0.509
t4 0.80 10 0.422 0.133 0.60 10 0.516 0.163
Type of inflammation t1 0.90 10 0.316 0.100 0.591 0.40 10 0.516 0.163 0.509
t4 0.80 10 0.422 0.133 0.60 10 0.516 0.163
ki67 t1 3.00 9 0.000 0.000 0.02 2.60 10 0.699 0.221 0.023
t4 1.78 9 0.833 0.278 1.60 10 0.966 0.306
PCnA basal t1 2.67 9 0.500 0.167 0.169 2.44 9 0.527 0.176 0.347
t4 2.22 9 0.667 0.222 2.22 9 0.667 0.222
PCnA suprabasal t1 3.00 9 0.000 0.000 0.169 3.00 9 0.000 0.000 0.081
t4 2.78 9 0.441 0.147 2.67 9 0.500 0.167
p53 basal t1 2.00 10 0.943 0.298 0.244 1.70 10 0.483 0.153 0.591
t4 1.50 10 0.850 0.269 1.50 10 0.972 0.307
p53 supra basal t1 2.20 10 0.632 0.200 0.193 2.30 10 0.949 0.300 0.087
t4 1.90 10 0.738 0.233 1.50 10 0.972 0.307
p21 suprabasal t1 1.56 9 0.527 0.176 0.193 1.20 10 0.789 0.249 0.758
t4 1.22 9 0.441 0.147 1.30 10 0.675 0.213
CD31 t1 28.67 9 16.815 5.605 0.103 31.40 10 13.251 4.190 0.017
t4 18.89 9 4.781 1.594 19.80 10 8.176 2.585
COX-2 t1 1.29 7 1.113 0.421 0.047 1.00 7 0.816 0.309 0.078
t4 0.57 7 0.787 0.297 0.57 7 0.787 0.297
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potential risk of progression to a more advanced disease 
and possibly invasive and metastatic SCC. 
Despite demonstrating itself to be an efficacious treat-
ment of clinically visible AK, even in high-risk organ 
transplant recipients (17, 27), the effects of 3% diclo-
fenac sodium with 2.5% hyaluronic acid in subclinical 
lesions (field cancerisation) have not yet been described. 
RCM is able to detect field cancerisation changes 
not only in the AK areas but also in “normal appearing 
skin” (subclinical AK) by visualisation of atypical 
honeycomb within the granular and spinous cell layer 
(17). In the present study, treatment with 3% diclofenac 
sodium in 2.5% hyaluronic acid was able to improve the 
epidermal atypia (evaluated as extension of the atypical 
honeycomb and degree of atypia in the honeycomb) 
even after only 2 weeks of treatment. This improvement 
persisted at the end of the study and correlated with the 
histological evaluation. However, there seemed to be 
an increased epidermal turnover suggested by the in-
creased presence of detached corneocytes and polygonal 
nucleated cells in the stratum corneum after 2 weeks 
of treatment. We hypothesise that these findings may 
be related to the induction of apoptosis of dysplastic 
keratinocytes induced by COX-2 inhibition as has been 
documented in a SCC cell line (22, 23). 
RCM revealed the appearance of intraepidermal 
inflammatory cells during the treatment course. These 
inflammatory changes were characterised by the pre-
sence of some small bright cells and some dendritic 
cells. We think these findings may be caused by a pro-
inflammatory microenvironment where interleukins 
and chemokines attract leukocytes that “repair” and 
“clear” the altered keratinocytes as a consequence of 
the induced apoptosis (18). However, contact dermatitis 
induced by the drug was not ruled out and the inflam-
mation seen clinically and by RCM could be due to this 
cause in some patients. 
Dermal collagen rearrangement in the superficial 
dermis was observed after the treatment course. The 
presence of huddles of collagen and curled fibres were 
observed previous to the treatment. These findings 
have been described in skin ageing and correlated 
with elastosis (36). We hypothesise that our finding of 
thickened collagen bundles after the end of treatment 
may be due to the effects of the topical hyaluronic acid 
stimulating dermal collagen production. Until recently, 
the hyaluronic acid was thought to serve as a “reser-
voir” that allowed the 3% diclofenac to accumulate as 
an intraepidermal depot (37), explaining the sustained 
clinical clearance of lesions even months after the end 
of treatment. However, recent data suggest that injected 
intradermal hyaluronic acid may stimulate dermal col-
lagen production even in aged skin (38). 
The immunohistochemical results are in accordance 
with previous findings that suggest that treatment with 
3% diclofenac in 2.5% hyaluronic acid gel causes 
regression of signs of cancerous transformation and 
inhibition of atypical keratinocyte proliferation (39). 
It is noteworthy that despite having a small number of 
patients the immunohistochemical results in this study 
showed that at the end of treatment, diclofenac sodium 
gel in hyaluronic acid was able to significantly modify 
epidermal atypia in both clinical and subclinical AK. 
This immunohistochemical finding correlated with 
the findings by RCM as shown in Fig. 2. Another re-
levant immunohistochemical result was the significant 
change in CD31 expression (a marker of angiogenesis) 
in subclinical AK at the end of treatment. This finding 
is consistent with previous results from other authors 
(24, 39) and likely related to the effects of the drug on 
COX-2 inhibition. 
The present study has some limitations due to the 
small sample size and being a non-randomised, uncon-
trolled study without long-term follow-up. Although the 
efficacy of diclofenac to treat AKs has been proven in 
controlled studies compared to vehicle, and it was not 
the aim of this study to show clinical response, it is not 
possible to rule out that some AKs were self-resolving 
as there was no comparison with a control group. The 
aim of this study was instead to show the morphological 
changes in clinical and subclinical AKs by RCM and 
its histopathological correlation.
RCM may bridge the gap between clinical evaluation 
and histopathologic evaluation allowing tissue analysis 
at near cellular resolution that is comparable to routine 
histology. It is particularly useful to non-invasively 
monitor treatment response. When evaluating patients 
with AKs, it provides the added benefit of allowing de-
tection and extension of field cancerisation (subclinical 
disease). 
In conclusion, our findings support the utility of RCM 
in the evaluation of field cancerisation and monitoring 
changes during therapy over time.  This information may 
add to our knowledge about the timing and characteristics 
of changes induced by any therapy. 
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